Allogene Therapeutics, Inc. (ALLO) KPIs and segments

ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30

$0.83−0.07 (-8.12%)

Close on Nov 12, 2026Market cap $285.72MP/E –Yield 0.00%

KPIs & segments

Operating metrics and segments that drive Allogene Therapeutics's business

Coming soon

This tab will track the numbers specific to Allogene Therapeutics's business model — such as store count, revenue by banner, revenue per store and new openings — taken from filings and earnings releases.

See a number that looks wrong?